# Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer

> **NCT00148668** · PHASE2 · COMPLETED · sponsor: **Eric Winer, MD** · enrollment: 81 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Herceptin
- **DRUG:** Navelbine
- **DRUG:** Taxotere
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00148668
- **Lead sponsor:** Eric Winer, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2009-01
- **Final completion:** 2011-08
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2013-04-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00148668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00148668, "Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00148668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*